Study on Effect of Astragalus Injection in Treating Pulmonary Heart Disease on Severe Stage:with 73 Cases

Objective: To observe the clinical efficacy and side-effects of Astragalus injection(AI) in treating congestive heart failure(CHF) on severe stage.Methods: 140 patients of CHF with heart function on 2~4 grade assessed by NYHA(New York Heart As-sociation) were randomly divided into 2 groups.The 73 patients in the treated group were treated with AI 40mL(equivalent to 80g crude drug) by adding in 5% glucose solution 250 mL for intravenous driping,once a day and the 67 patients in the control group were treated by nitrolingual injection 15mg by adding in 5% glucose solution 500mL for intravenous in-jection driping,once a day,The therapeatic course in both groups were 10 days and the patients were followed-up for 1-6 months.Results: the clinical heart function improvement rate and the total effective rate in the treated group after 1 month treatment were 26.2% and 78.6%,and after 6 months were 34.2% and 81.6% respectively,which were superior to those in the control group significantly(P 0.05 or P 0.01).The levels of left ventricular ejection fraction(LVEF),fractional shortening of left ventricular short axis(FS),the ratio of maximum blood flow between the advanced and early atrial systole(E/A),stroke volume(SV),cardiac output(CO),and the cardiac index(CI) were all improved in both groups(P 0.01 or P 0.05),but better improvement were shown in the treated group.Followed-up study showed that the incidence of cardiac event were lower in the treated group than that in the control group(P 0.05).Conclusions: AI can be took as one of the important auxiliary drugs treatment of CHF especially in severe case.